Lelie P N, van Amelsfoort P J, Martine de Groot C S, Bakker E, Schaasberg W, Niessen J C, Reesink H W
Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam.
Hepatology. 1989 Jul;10(1):36-8. doi: 10.1002/hep.1840100109.
In a randomized, dose-response study among 305 health care workers, we examined whether the immunogenicity of a heat-inactivated hepatitis B vaccine could be enhanced when HBsAg was complexed by anti-HBs contained in hepatitis B immunoglobulin either at equivalent proportions or at 10-fold antigen excess. The dose of HBsAg in the control vaccine as well as in the two complexed vaccine preparations could be reduced from the standard value (3 micrograms) to 0.6 micrograms per injection without affecting the antibody response in the vaccinees. Still lower dosages of HBsAg in the three vaccine preparations induced significantly lower but comparable anti-HBs responses. These results indicate that, in man, using a heat-inactivated plasma vaccine, addition of anti-HBs contained in hepatitis B immunoglobulin does not potentiate the immunogenicity of HBsAg.
在一项针对305名医护人员的随机剂量反应研究中,我们研究了在乙肝免疫球蛋白中所含的抗-HBs与HBsAg以等比例或抗原过量10倍的方式形成复合物时,热灭活乙肝疫苗的免疫原性是否会增强。对照疫苗以及两种复合疫苗制剂中的HBsAg剂量可从标准值(3微克)降至每次注射0.6微克,而不影响疫苗接种者的抗体反应。三种疫苗制剂中更低剂量的HBsAg诱导的抗-HBs反应显著更低,但具有可比性。这些结果表明,在人体中使用热灭活血浆疫苗时,添加乙肝免疫球蛋白中所含的抗-HBs不会增强HBsAg的免疫原性。